Companies › Sandoz
1 active drug program in 1 registered trial: 1 Phase 3; Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ocrelizumab (CYB704) B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Relapsing Multiple Sclerosis | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06847724 | Ocrelizumab (CYB704) | Phase 3 | Relapsing Multiple Sclerosis | Neurology | Nov 2026 |
Roche Biocad Acerta Pharma Regeneron Pharmaceuticals Celltrion TG Therapeutics Genmab Novartis AbbVie AstraZeneca
Merz Pharmaceuticals Lupin Neurona Therapeutics Cytopeutics Sdn. Bhd. NKGen Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.